Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E. Walsh, William C. Gruber, Kena A. Swanson et al.|New England Journal of Medicine|2020Cited by 2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J. Mulligan, Kathrin U. Jansen, Kirsten E. Lyke et al.|Nature|2020Cited by 1.6k
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy StudyEdward E. Walsh, William C. Gruber, Robert W. Frenck et al.|medRxiv|2020Cited by 155
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim ReportMark J. Mulligan, Kathrin U. Jansen, Kirsten E. Lyke et al.|medRxiv|2020Cited by 124
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J. Mulligan, Kathrin U. Jansen, Kirsten E. Lyke et al.|Nature|2021Cited by 28